Spots Global Cancer Trial Database for a Single-arm, Single-center, Open Clinical Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: a Single-arm, Single-center, Open Clinical Study

Official Title: Clinical Study on the Safety and Efficacy of GK01 Autologous Tumor-reactive T Cells (TRT) in Patients With Advanced Solid Tumors

Study ID: NCT06431100

Conditions

Gastric Cancer

Esophageal Cancer

Cervical Cancer

Non-Small Cell Lung Cancer NSCLC

Triple Negative Breast Cancer TNBC

Interventions

TCR T-cells

Study Description

Brief Summary: This trial plans to enroll many patients with advanced solid tumors to complete GK01 cell transfusion, including but not limited to advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, and non-small cell lung cancer. For patients with advanced solid tumors eligible for inclusion, autologous tumor-reactive T cells (experimental drug GK01) were cultured and prepared, and a certain dose of GK01 cells was given according to the cell transfusion plan, and the safety and tolerability of the patients after transfusion were observed. Exploratory evaluation of pharmacokinetic/pharmacodynamic profiles following reinfusion and initial evaluation of efficacy of investigational drug GK01 cells according to RECIST 1.1 criteria.

Detailed Description: